Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

March 18, 2021 By Cade Hildreth, Founder & President Leave a Comment

FLORHAM PARK, N.J., March 18, 2021 — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced that the company has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme (GBM). CYNK-001 is currently being investigated in multiple clinical trials, including a Phase 1 clinical trial for GBM. [Read more…]

Celonic to Expand Cell and Gene Therapy CDMO Business with Facility in Switzerland

March 16, 2021 By Cade Hildreth, Founder & President Leave a Comment

Celonic to Boost Its Cell and Gene Therapy (CGT) Production with a Facility in the Upcoming Life Science Parket Rheintal, located in Stein, Switzerland.

Celonic Group, a leading global CDMO specializing in the development and production of Advanced Therapy Medicinal Products (ATMP) and bio-therapeutics, announced a long-term lease agreement for a new production site and office space. The facility will span 91,500 square feet (8,500 sqm) in the WST-222 building at the Novartis-operated Life Science Park Rheintal. [Read more…]

Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie

March 14, 2021 By Cade Hildreth, Founder & President Leave a Comment

Pharmaron Continues to Expand Its Capacity to Offer Commercial Manufacturing Services for CGT Products

February 28, 2021, BEIJING–Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) has entered into a definitive agreement to acquire Allergan Biologics Limited (“The ABL site”) in Liverpool, UK, for US$118.7 million in cash from AbbVie. The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions. [Read more…]